

# Review of: "Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients"

Vijay Mishra

Potential competing interests: No potential competing interests to declare.

The author study group had attempted a nice effort to study the, the native medicine effect over the prescribed medication for the COVID-19 treatment. However, I have certain queries regarding the manuscript which are listed below:

1. There are few grammatical error in the manuscript.
2. The sample size of the study as the COVID-19 is pandemic disease.
3. The Baricitinib intervention group has higher number of patients with the diabetes which, one of the major risks for COVID-19 associated mortality. Further, the study shows that Baricitinib group have higher mortality. So, the underlying cause of mortality in this group is not clear.
4. Please mention the inclusion and exclusion criteria of the study and how you selected the sample size for the study.
5. The Discussion part is missing, the present manuscript is incomplete.

I will not recommend the present article to proceed it further.